StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Earnings

Enliven Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.36
-$0.32 a year earlier
Latest guidance
Lowered
Mar 15, 2022 · 2 items

Quarterly results

Revenue and earnings per share from each of Enliven Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close––-$0.36Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close––-$0.38Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close––-$0.32Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 14, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025after the close––-$0.46Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024after the close–––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close––-$0.41Release
Q1 FY2024ended Mar 31, 2024May 14, 2024after the close––-$0.54Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Enliven Therapeutics guided for has been reported

Guidance history

Every forecast Enliven Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 15, 2022research and development expensesFY2022$60.00M – $65.00MNew
Mar 15, 2022general and administrative expensesFY2022$13.00M – $15.00MLowered
Nov 9, 2021research and development expensesFY2021$40.00M – $45.00MNew
Nov 9, 2021general and administrative expensesFY2021$12.00M – $13.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Enliven Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Update
  5. Update
  6. Results
  7. Results
  8. Update
  9. Results
  10. Results
  11. Results
  12. News
  13. Update
  14. Results
  15. Results

See a number that looks wrong?